Johns Hopkins spinout Blade Therapeutics has agreed to a reverse merger that will net it $24.3m in Pipe financing from backers including Osage University Partners.

Blade Therapeutics, a US-based fibrosis treatment developer spun out from Johns Hopkins University, has agreed to a reverse merger with special purpose acquisition company Biotech Acquisition Company. The merger is expected to occur in the first quarter of 2022, whereupon Biotech Acquisition Company will be rebranded to Blade Biotherapeutics and list on Nasdaq using the…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.